•
Mar 31, 2021
PMV Pharma Q1 2021 Earnings Report
Reported financial results for Q1 2021 and provided corporate highlights.
Key Takeaways
PMV Pharma reported a net loss of $11.6 million for the quarter ended March 31, 2021. The company ended the quarter with $348.4 million in cash, cash equivalents, and marketable securities. Enrollment in the Phase 1/2 trial of PC14586 is progressing as planned.
Presented preclinical data on PC14586 at the American Association for Cancer Research Annual Meeting 2021.
Continued to enroll patients in the Phase 1 portion of a Phase 1/2 clinical trial of PC14586.
Expanded Board of Directors with the appointment of Charles M. Baum, M.D., Ph.D.
Expanded Scientific Advisory Board with the appointment of Guillermina (Gigi) Lozano, Ph.D.